Better Science, Better Health: New Trial Pathways and Better Patient Data
| INTRODUCTION | AGENDA | SPEAKERS | DOWNLOADS | PICTURES/VIDEOS |CONFERENCE REPORT |
SPEAKERS
|
|
Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to over 225 today.Previously Dr. Abrahams was executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania. |
|
|
Iftakhar Ahmed has over 16 years’ experience as chief strategist in high tier, full-service digital and performance marketing agencies. He has managed delivery of world-class global projects, created and run multiple agency teams, won and sustained senior client relationships for blue-chip brands including; Vodafone, Microsoft, Merck Sharp & Dohme, GSK, Reuters and Visa. Having co-founded and run an award-winning agency in the 1990s, Ifty became Head of Digital at IMG Media and Vivid Lime, before taking global responsibility for The Collinson Group as Global Head of Digital and Customer Engagement. Ifty founded Pow Health in March 2012 aiming to create a site offering the user a completely safe and secure and effortless way to manage ‘all your health in one place’. Ifty is a creative technologist, passionate about empowering people so that they can better manage their health, support one another and help create better treatments for everyone. This is the focus behind Pow Health. |
|
|
Mohammad is founder and CEO of Patients Know Best and has over 15 years of experience in medical software. He trained as a physician at the University of Cambridge; worked as a staff scientist at the National Institutes of Health; and was a management consultant to US hospitals at The Advisory Board Company. He is the author of seven books, including Personal health records: A guide for clinicians and Streamlining Hospital-Patient Communication: Developing High Impact Patient Portals.He is also an honorary senior research associate at UCL medical school for his research on patient-controlled medical records. In 2012 he was elected an Ashoka Fellow as a social entrepreneur for the contributions he has made to patient care. |
|
|
James has worked at GSK for the last 10 years on improving the way we develop and commercialise our products by working in partnership with stakeholders. Working collaboratively, he addresses significant health policy issues, often conducting pilots with stakeholders. For example, James led GSK’s engagement with EU payers, politicians and HTA agencies, under the European Healthcare Innovation Leadership “Tapestry” Network, which delivered the first multi-country parallel advice process. Building on this, he is currently working to improve patient access via Medicines Adaptive Pathways to Patients (MAPPs, or adaptive licensing). James participates in MIT’s NEWDIGS programme and leads much of GSK and EFPIA’s advocacy in this area and helps drive GSK’s pilot assets within the EMA AL programme. James also leads GSK advocacy in the area of Antimicrobial Resistance, launching the ground-breaking >€650m Innovative Medicines Initiative (IMI) AMR project with the EU Commission and participating in work with Chatham House, Brookings and UK Government programmes. Prior to this, James has held a number of Commercial roles at GSK and Shire Pharmaceuticals. James is Vice-Chair of the industry Healthcare Taskforce advising the OECD. He has a MBA from Harvard Business School and a Molecular Biology degree from Cambridge. |
|
|
During the past 15 years Andrea has worked in the areas of Statistics and Epidemiology, both in the US and in Europe, for several private and public organizations. For the past 4 years, under a collaborative agreement with the University of Groningen, the Netherlands and the European Medicines Agency, Andrea formed part of a small team of experts providing research support for the EMA Benefit-Risk Methodology project. Her research areas of interest are measuring individual differences in risk attitude, risk perception, and elicitation of treatment preferences among patients, regulators and healthcare professionals. From October 2012 to December 2013 Andrea provided scientific leadership for the EMA Benefit-Risk Methodology project and since January 2014 has provided leadership for a European-wide study on extending benefit-risk methodologies to patients and healthcare professionals under Work Package 6 of the IMI-PROTECT project (www.imi-protect.eu). |
|
|
Professor Barker has been Director of CASMI since its creation and was instrumental in its inception and launch. He is a strategic advisor, speaker and author on healthcare and life sciences. Richard’s 25-year business career has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. Most recently he was Director General of the Association of the British Pharmaceutical Industry, member of the Executive Committee of EFPIA (the European industry association) and Council member of IFPMA (the international equivalent).His past leadership roles include head of McKinsey’s European healthcare practice, General Manager of Healthcare Solutions for IBM and Chief Executive of Chiron Diagnostics. He was also Chairman and Chief Executive of Molecular Staging, aUSbioscience company, now part of Qiagen.In addition to leading and advising a wide range of companies, Richard has advised successive UK governments on healthcare issues, and in particular, on developing, valuing and using new healthcare technologies. His was co-founder of Life Sciences UK, a member of the NHS Stakeholder Forum, and vice-chair of the UK Clinical Trials Collaboration. He is also Chairman of Stem Cells for Safer Medicines, a public-private partnership developing stem cell technology for predicting the safety profile of new medicines, and a board member of iCo Therapeutics, a Canadian bioscience company. |
|
|
By approaching every project with vigour, Jack has developed everything from patient centred systems to medicine adherence programs to multi-system integrations and much more! At HandleMyHealth Jack works to develop a medication compliance and quality of life support system for more personalized medicine and more effective treatment. |
|
|
Chairman of the executive committee, European Network for Health Technology Assessment (EUnetHTA) and director of its coordinating secretariat, National Board of Health, Denmark since 2009. Adjunct professor in health services research and health technology assessment at University of Southern Denmark from 1999.Formerly director of the Danish Centre for Health Technology Assessment (DACEHTA), National Board of Health, Denmark 1997-2009. University graduate in medicine, PhD in epidemiology and medical specialities as primary care and public health physician. Involved with international projects in health services research, epidemiology, health technology assessment, and clinical practice guidelines since the 1980ies.Past chairman of the International Network of Agencies for Health Technology Assessment (INAHTA) (2003-2006), member of the ISPOR Board of Directors (2011-13). Project leader of EUnetHTA, (2006-2008; www.eunethta.net), editor of Health Technology Assessment Handbook (English, translated), 2007, and chief editor of three peer reviewed publication series from DACEHTA 1998-2009. |
|
|
Helmut Brand is Jean Monnet Professor of European Public Health and head of the Department of International Health at Maastricht University, The Netherlands. He studied Medicine in Düsseldorf and Zürich and holds a Master in Community Medicine from London School of Hygiene and Tropical Medicine and London School of Economics. Prof. Brand is a specialist in Public Health Medicine. After working in several Health Authorities and Ministries of Health he was director of the Public Health Institute of North-Rhine Westphalia, Germany. Since then European Integration in Health is the main topic of his work. He is past-president of the Association of Schools of Public Health in the European region (ASPHER) and president of the European Health Forum Gastein (EHFG). As policy advisor he serves on the European Advisory Committee on Health Research (EACHR) of WHO Europe and on the Expert Panel on “Investing in Health” (EXPH) for the European Commission. He is member of the steering committee of the Maastricht Centre for European Governance – a Jean Monnet Centre of Excellence. |
|
|
John has joint responsibility for the development of IBM’s Healthcare Business in Europe. He is a member of several healthcare IT industry associations, including COCIR and Continua, and he is currently Vice President of the European Health Telematics Association (EHTEL). He served on the Industry Team for epSOS, and is the lead IBM representative for the European Innovation Partnership on Active and Healthy Aging (Action Area B3 – Integrated Care). He is often invited to provide expert commentary about developments in eHealth, and has spoken at many conferences and events including MedTec Europe, European Radiology Congress, World of Health IT, European Health Forum Gastein, eHealth Forum, HIMSS CIO Summit, European Telemedicine, Economist Digital Horizons, Danish eHealth Observatory, and the NHS Confederation Conference. In 2012 he contributed to the World Economic Forum report on Sustainable Healthcare Systems, and in 2010 he designed and taught a class on the evolution of eHealth at the J&J European Health Leadership Programme at the INSEAD Business School. With over 33 years experience in the IT Industry, he is a strong advocate for the transformation of healthcare using information technology, and he regularly provides briefings on IBM’s Healthcare Business and eHealth to the press and analysts. |
|
|
Wendy Currie is Professor of Information Systems at Audencia, School of Management, Nantes, France. She is Editor-in-Chief of the new FPM journal Health Policy and Technology. Her research focuses on ICT and health policy and practice. |
|
|
Hans-Georg Eichler, M.D., M.Sc., is the Senior Medical Officer at the European Medicines Agency in London, United Kingdom, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues. From January until December 2011, Dr. Eichler was the Robert E. Wilhelm fellow at the Massachusetts Institute of Technology’s Center for International Studies, participating in a joint research project under the MIT’s NEWDIGS initiative. He divided his time between the MIT and the EMA in London. Prior to joining the European Medicines Agency, Dr. Eichler was at the Medical University of Vienna in Austria for 15 years. He was vice – rector for Research and International Relations since 2003, and professor and chair of the Department of Clinical Pharmacology since 1992.His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association.His industry experience includes time spent at Ciba-Geigy Research Labs, U.K., and Outcomes Research at Merck & Co., in New Jersey. Dr. Eichler graduated with an M.D. from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, U.K. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University. |
|
|
Dr. Esserman is a surgeon and breast cancer oncology specialist, and is the Director of the Carol Franc Buck Breast Care Center at the University of California, San Francisco (UCSF). In 1996, she started the Center of Excellence for Breast Cancer Care at UCSF to integrate clinical care and research, automate tools for the capture of patient and clinical data, and develop systems to tailor care to biology, patient preference, and performance.Dr. Esserman is nationally and internationally known as a leader in the field of breast cancer and has published over 200 articles. She served as a member of a taskforce for President Obama’s Council of Advisors on Science and Technology (PCAST) Working Group on Advancing Innovation in Drug Development and Evaluation. The group was tasked with making recommendations to the federal government about how to best support science-based innovation in the process of drug development and regulatory evaluation.She is the Principle Investigator of the I-SPY TRIAL program, a multi-site neoadjuvant clinical trial (which includes a phase 2 and 3 trial) that has evolved into a model for translational research and innovation in clinical trial design. Dr. Esserman has recently launched a University of California-wide breast cancer initiative called the Athena Breast Health Network, a program designed to follow 150,000 women from screening through treatment and outcomes, incorporating the latest in molecular testing and web-based tools into the course of care. Athena is in the final stages of launching a statewide demonstration project and phase 1/phase 2 trial of personalized screening. |
|
|
Gary Finnegan is an award-winning journalist, editor and author, with a particular interest in health, research and innovation policy. He has written and edited a range of magazines, newspapers and websites, including EurActiv, where he was science and health section editor. Gary has also written extensively for the pharmaceutical, vaccine and medical technology industries. He has a degree in physiology and a Masters degree in science communication.He has been a national winner (Ireland) of the EU Health Prize for Journalists on three occasions, was named Irish Medical Columnist of the Year in 2013, and has written a book about China. |
|
|
George was elected to Parliament in May 2010 after a 15 year career in and around the Cambridge cluster supporting high growth businesses. He won the 2010 election for the new constituency of Mid Norfolk, with a majority of 14,000, after an innovative campaign (It Starts Here!) focussed on the need for a fresh start in politics. Founder of the Mind The Gap! and Positive Politics campaigns, and a passionate advocate of the role of enterprise in a renaissance of civic responsibility, he narrowly missed capturing Stevenage for the Conservatives in 2005 with one of the biggest swings of the 2005 election. George has written and spoken widely on the potential of Britain’s science and innovation economy to support a sustainable economic recovery and unlock huge trade and inward investment opportunities in fast emerging global markets. Following the 2010 election he was appointed PPS to the Minister for Climate Change, Greg Barker MP and elected Chairman of the All-Party Parliamentary Group on Science & Technology in Agriculture. In 2011 he was appointed Government Adviser on Life Sciences to the Minister of State for Universities and Science, Rt Hon David Willetts MP. In this role he was closely involved in the development and implementation of the Government’s Life Science Strategy announced by the PM in December 2011, and is actively working with UKTI to promote the UK Life Science sector including representing the UK Government on UKTI trade missions to the USA and Sweden. Highlighting the importance of modern road, rail and broadband infrastructure to unlock a sustainable innovation economy in the East of England, George has played a central role in the successful campaigns to upgrade the Cambridge-Norwich railway and Ely Junction bottleneck, secure the Government funding for the dualling of the A11, and raise the £60m for fast rural broadband in Norfolk. Founder of The Norfolk Way project to promote and pioneer a new model of a decentralised rural innovation economy, he works closely with local schools and businesses in setting up The Norfolk Way Bursary and Work Club, and promote a renaissance of rural entrepreneurship. |
|
|
Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne). Its mission is to improve the treatment, quality of life, and long-term outlook for all individuals affected by Duchenne through research, advocacy, education, and compassion.Duchenne is the most common fatal, genetic childhood disorder, which affects approximately 1 out of every 3,500 boys each year worldwide. It currently has no cure. |
|
|
Dr Sarah Garner PhD, BPharm is a pharmacist specialising in Health Technology Assessment (HTA). Sarah is the Associate Director for R&D at the UK’s National Institute for Health and Clinical Excellence (NICE) and is responsible for the planning and delivery of NICE’s R&D agenda relating to methodology and clinical research.Sarah is also Project Director for Adaptive Licensing at the newly formed Centre for the Advancement of Sustainable Medical Innovation, a partnership between the University of Oxford and UCL. In 2010-11 Sarah was a Harkness Fellow in Healthcare Policy and Practice in the United States. Her research examined the impact of comparative effectiveness research and HTA on innovation. Sarah is working with the NEWDIGS team at MIT to identify R&D policy solutions using a systems approach.Sarah is on the UK Regulation of Medicines Review Panel, which carries out independent reviews of UK licensing authority decisions. |
|
|
Michel Goldman is the chief executive responsible for the management of IMI in accordance with the decisions of the Governing Board. He is supported by the staff of the Executive Office. As the Executive Director of IMI, he builds and promotes networks of innovation, in close collaboration with all stakeholders involved in pharmaceutical R&D. He supports the launch and successful continuation of collaborative programmes to foster research and development activities on more effective and safer therapies for patients across Europe.Michel Goldman is Professor of Immunology at the Faculty of Medicine of the Université Libre de Bruxelles (Belgium).His achievements in the fields of immune-mediated disorders and immune-based biotherapies resulted in more than 400 articles in peer-reviewed journals. In 2004, Michel Goldman started up the Institute for Medical Immunology (Charleroi, Belgium) as the first public-private partnership in the biomedical sector in Wallonia and he has been the first vice-president of the BioWin Health Cluster created to foster networks between industries and academic institutions in this region. From 2007 to 2009, he served the European Research Council as a member of the Advisory panel on Immunology and Infectious Diseases.In 2000, Michel Goldman received the Joseph Maisin Prize, a major award for clinical sciences delivered by the Belgian Fund for Scientific Research, and he held the Spinoza chair at the University of Amsterdam in 2001. He was recognized as ISI Highly Cited Scientist by the Thomson Institute for Scientific Information in 2006. Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université Lille II (France) in 2007 |
|
|
Adam is Senior Director in Pfizer’s Global Health and Value Innovation Centre. The centre is a new team set up to take a longer term look at issues determining market access for new medicines. Previously, Adam has worked for Pfizer’s International Policy and Science Policy teams working on projects related to HTA reform, real world data, orphan drugs and rare diseases, R&D productivity, collaborative research, stem cell science and personalised medicine. Before joining Pfizer nine years ago, Adam worked for a variety of government and public sector organisations, including the Prime Minister’s Strategy Unit – on GM crops and innovation policy; the House of Lords Science and Technology Committee – on topics from complementary medicine to human genetic databases; and the Commission for Patient and Public Involvement in Health – bringing the views of local people and voluntary organisations to health service decision-makers. Adam also spent three years as a post-doctoral researcher at the Rutherford Appleton Laboratory, Oxfordshire. He has a PhD in chemistry. |
|
|
Jeremy Haigh is responsible for Amgen’s Research & Development sites across Europe, the Middle East and Africa (EMEA), and for Global Development staff located in the region. He is a director of Amgen Limited, BioVex Limited, and the recently acquired Amgen Research (Munich) GmbH, a member of the Global Development Senior Leadership Team and of Amgen’s European Management Committee. He is based at the European R&D headquarters in the UKJeremy has spent over 25 years in the bioscience sector in a variety of clinical research, development, operational and leadership roles. He has experienced both traditional pharmaceutical and biotechnology environments at Merck (1988 – 1995) and at Amgen (since 1996) where latterly he has been deeply involved in the organizational development, governance and asset integration associated with a rapidly expanding company.He has a long standing interest in novel approaches to neurological disease, and has been closely associated with the development and registration of a number of new molecular entities in different therapeutic areas.Jeremy graduated in pharmacology from the University of Leeds (1982), received a Ph.D. in neuro-pharmacology (1985) and completed a post-doctoral research fellowship in clinical pharmacology. He has held university teaching and examining positions, and authored over 30 peer reviewed publications. Jeremy is a Director of the BioIndustry Association (BIA) and a member of The Association of the British Pharmaceutical Industry (ABPI) Innovation Board. He represents Amgen at the EFPIA Research Directors Group and attends various UK government-led committees. |
|
|
Joel leads the overall healthcare strategy and business development in EMEA, working across the Oracle Health Sciences Global Business Unit strategy, alliance, sales, consulting and solution consulting teams as well as the extended technology, applications and Industry Business Unit groups.Leveraging his 25 years of consulting and IT experience, of which 14 have been exclusively focused on healthcare, Joel works closely with the Oracle Health Sciences Network, Enterprise Health Analytics, Translational Research Center and Health Information Exchange product strategy team.Prior to joining Oracle in 2011 he served as CEO of Sentient Health, an innovative supply chain and analytics software provider with customers in Europe and Asia. The company was acquired in 2011. He also spent 10 years with Deloitte Consulting, delivering technology-enabled business solutions in the United States, Australia and Asia where Joel was instrumental in the development of Deloitte Consulting methodologies and international expansion. |
|
|
Ryan Hohman, JD, serves as Managing Director, Policy & Public Affairs at Friends of Cancer Research (Friends), a think tank and advocacy organization based in Washington, D.C. Friends is the U.S.’s leading voice in advocating for policies and proposing and promoting real solutions that will get treatments to patients in the safest and quickest way possible.At Friends, Ryan leads the strategic development and execution of public-policy and legislative initiatives to enhance U.S. Food and Drug Administration regulatory policies and Department of Health and Human Services, and its institutes, research programs. Additionally, Ryan oversees the organizations targeted outreach, comprehensive communications strategy, federal affairs, advocacy relations, and the organizations development programs. As Managing Director of Policy & Public Affairs at Friends, Ryan has the privilege of serving on many important boards and committees of organizations who share Friends mission, including: Advisory Council, Enroll America; Principles Working Group, National Dialogue for Healthcare Innovation (NDHI); Strategic Advisory Committee, The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown – Lombardi CCC; Advisory Council, Capital Breast Care Center (CBCC).Before joining Friends, Ryan was Director of Corporate and Institutional Partnerships at Georgetown University’s Lombardi Comprehensive Cancer Center.While at Georgetown, Ryan focused on the development and execution of strategic corporate and philanthropic engagement to support the center’s biomedical research and cancer treatment and education programs. During this time, Mr. Hohman was appointed to the Board of Directors of the Cancer Research Alliance and worked to support and expand the programs of the Capital Breast Care Center, which provides comprehensive, culturally appropriate breast cancer screening services and health education to women in the Washington, DC metropolitan area.Prior to his time at Lombardi, Ryan was an associate with a DC & Boston-based public relations firm, specializing in health and trade association media and governmental strategy. Ryan has also served in numerous political campaigns and offices, including: former Senate Majority Leader Tom Daschle’s 2004 Senate race, Senator John Edwards’ Presidential Campaign, and at the Democratic National Committee under then Chairman Terry McAuliffe. |
|
|
Alastair Kent OBE is the Director of Genetic Alliance UK – the national charity of over 150 patient organisations, supporting all those affected by genetic conditions. Genetic Alliance UK’s mission is to promote the development of the scientific understanding of genetics and the part that genetic factors play in health and disease, and to see the speedy transfer of this new knowledge into improved services and support for patients.Alastair is also the Chair of Rare Disease UK (RDUK) the national alliance for people with rare diseases and all who support them. RDUK has over 1,200 members including over 220 patient organisations, health professionals, researchers, the pharmaceutical industry and individual patients and families.Alastair has worked in the field of genetic and rare disease healthcare for over 20 years.Alastair represents the interests of patients on numerous platforms; he is the president of the European Genetic Alliances Network (EGAN), Immediate Past Chair of the European Platform for Patient Organisations, Science and Industry (EPPOSI) and the EU Committee of Experts on Rare Diseases amongst others. He has previously been a member of the Orphan Medicinal Products Committee and Committee for Advanced Therapies at the European Medicines Agency and a member of the Human Genetics Commission. |
|
|
Faraz Kermani is a a journalist and editor at the Pink Sheet, a US-based publication that covers the global pharmaceutical market. He has a B.A. (Hons) in German and Scandinavian Studies and an M.A. in European Law, with a specialisation in pharmaceutical law.He has over 16 years of experience as a journalist and communications specialist in the healthcare and pharmaceutical sectors, working on titles that include: Clinical World Medical Devices and Diagnostics Newsletter, Scrip, the Regulatory Affairs Journal and The Pink Sheet. |
|
|
Yann Le Cam is a patient advocate who has dedicated 25 years of professional and personal commitment to health and medical research non-governmental organisations in France, Europe and the United States in the fields of cancer, HIV/AIDS and rare diseases.He has three daughters, the eldest of whom has cystic fibrosis. Yann is one of the founders of EURORDIS in 1996-1997 and its Chief Executive Officer since 2001.He has participated to the revision and adoption of European regulations having an impact on rare disease patients’ life, including the EU Regulation on Orphan Drugs, December 1999.He was one of the first patient representatives appointed to the Committee for Orphan Medicinal Products (COMP) at the European Drug Agency (EMA) where he served for 9 years and was its Vice Chairman for 6 years. He served on the Management Board and Executive Committee of the French HTA agency for 5 years, on the DIA Advisory Committee Europe for 3 years.He was the Vice Chairman of the EU Committee of Experts on Rare Diseases (EUCERD) from 2011 to July 2013, and he is nominated on the current Commission Experts Group on Rare DiseasesIn November 2013, Yann Le Cam was elected Chair of the Therapies Scientific Committee of the IRDIRC – International Rare Diseases Research Consortium. |
|
|
At the end of Medical School, after one year of Pharmaceutical Medicine program and a DES in management, S. Marreaud began her career as medical fellow at EORTC and had the opportunity to be exposed to full range of trainings, all of which tended to reinforce and solidify her intense interest in clinical research. After her fellowship, she was appointed as project leader for early phase trials and developed her expertise in the management of phase I trials and methodology for safety evaluation. Since her main interest remained scientific, she did pursue experience in clinical trials by taking over the position of clinical research physician in several EORTC disease oriented groups such as Breast, Chronotherapy, Gastro-Intestinal, Genito-Urinary, Soft Tissue and Bone Sarcoma (STBSG) and Melanoma groups. Her cooperation with the STBSG gave her opportunities to extend her knowledge and experience in rare disease field and in management of international trials. Since 2011, she has been appointed as Head of Medical and Pharmacovigilance Department and more recently also involved in the coordination of the EORTC Brain Metastases Research Platform. |
|
|
Jillian Oderkirk is a Senior Economist and Policy Analyst with the Health Division of the Organisation for Economic Co-operation and Development in Paris, France. She leads a project on developing health information infrastructure including the development of electronic health record systems; the use of personal health data for health system performance monitoring and research; and the privacy and data protection challenges associated with the secondary use of data. Jillian also leads efforts to model health systems within the OECD including the development of decision-support platforms and health expenditure forecasting methods. Prior to joining the OECD, Jillian had a long carreer with Statistics Canada in Ottawa, Canada and was the Director of the Health Analysis Division at Statistics Canada from 2006 to 2011. Jillian has a Master’s Degree in economics from McMaster University, Hamilton, Canada. |
|
|
Bettina Ryll founded the Melanoma Patient Network Europe in 2011. Bettina holds a medical degree and a Phd in biomedical sciences and the experience of her husband participating in several clinical trials after having been diagnosed with metastatic Melanoma at the age of 36 ultimately changed her perspective on clinical research. She strongly advocates for patient-centered trial designs and innovation-sustaining drug developments concepts integrating wide-spread early access to innovative oncology drugs with systematic learning and continuous evaluation. Bettina is also going to be the next chair of the ESMO cancer patient working group, the first time that this position will be held by a non-oncologist. |
|
|
Duane is the Managing Director of Vital Transformation. He regularly consults to National health authorities, blue chip multi-national organisations, governments, and stakeholder groups on healthcare policy and technology. He is a regular speaker at many leading international conferences including the European Health Forum Gastein, London Genetics, DIA, and the Royal College of Physicians. Mr. Schulthess has also collaborated with Professor Henry Chesbrough in establishing the European Innovation Forum and is a member of the advisory board of Health Policy and Technology. Duane was the EMEA Head of Corporate Development of The Wall Street Journal. He was also, for five years, the Commercial Director of Science|Business, establishing and building their successful Brussels consultancy practice. |
|
|
Cornelius Schmaltz received his MD and his training as a board-certified paediatrician from the University of Freiburg/Germnany. Following a postdoc at Dana-Farber Cancer Institute in Boston and a fellowship in Pediatric Hematology/Oncology at Memorial Sloan-Kettering Cancer Center in New York, Dr. Schmaltz joined the Volkswagen Foundation in Germany, as programme manager in Medicine.Since 2006 he has been an official at the European Commission’s Research and Innovation Directorate General, where he is currently Deputy Head of Unit for Infectious Diseases and Public Health. In 2012 Dr. Schmaltz obtained a (distance-learning) M.A. in International Relations from the Free University in Berlin. He is the co-author of 11 original papers in peer-reviewed journals, including Nature Medicine and Nature Genetics. |
|
|
Nathalie is Senior Scientific Project Manager at IMI (Innovative Medicines Initiative) responsible for the coordination and management of projects within the scientific team. Having a regulatory background, liaison for regulatory matters.Before joining IMI in 2011, she was a scientific administrator at the European Medicines Agency (EMA) where she first gained experience in the centralised procedures and other activities related to the evaluation of marketing authorisation applications (mostly in relation to anti-infectives) and later on the paediatric development with the implementation of the EU Paediatric Regulation at the Agency level. |
|
|
Dr Siviero is Coordinator of the “Economic Strategy and Pharmaceutical Policy” area that consists of departments responsible for pharmaceutical policy, pricing reimbursement, medicines utilization and HTA and consultative bodies secretariat He is also the Head of the Pharmaceutical Policy department of the Italian Medicines Agency (AIFA). The main objective of the Pharmaceutical Policy department is to perform and evaluate studies and research on the pharmaceutical sector, The primary objective is to supervise the main activities of the Agency in the economic field and to define the pricing and reimbursement scheme for new pharmaceutical products, taking into account the analysis of other European agencies.As coordinator of the “Economic Strategy and Pharmaceutical Policy” department, Mr. Siviero is responsible for anticipating and analysing critical aspects relating to the sustainability of the National Health System, concerning the pharmaceutical sector. During his career, Mr. Siviero has cooperated with the National Research Council, in particular with the research Institute of neurobiology and molecular medicine (INMM), regarding the development of issues such as the technological transfer, knowledge management and the economical valorisation of results obtained through research. Mr. Siviero has also been CEO in companies dealing with communication and public relations in the health sector. |
|
|
Olga studied Chemistry at the Aristotle University of Thessaloniki, Greece and holds an MSc in Food Science from the Goteborg University, Sweden. Before joining the European Commission she worked for 5 years as Quality Control Supervisor in a soft drinks and beverage producing company in Greece. She joined DG SANCO in 2001 and worked for 10 years in the field of ‘Safety of the food chain’ in the areas of Food Contact Materials, Food Additives and Enzymes. In 2010, she moved to the Directorate ‘Health Systems and Products’ where she worked in the field of substances of human origin before taking up a post in the pharmaceutical sector in 2011. She is currently Deputy Head of the SANCO Unit responsible for medicinal products – authorisations and relations with EMA. |
|
|
Sir Richard trained in natural sciences and medicine at Oxford and St Thomas’ Hospital Medical School. After junior posts in London, he joined Dr Roger Williams in the early days of the liver unit at King’s College Hospital, and spent 18 months with Professor Alan Hofmann at the Mayo Clinic. In 1972 he was appointed physician and gastroenterologist at St Thomas’ Hospital until his retirement in 2005. He led an active clinical research laboratory for over 30 years, chiefly studying various aspects of nutritional gastroenterology, as well as supervising 30 MD and PhD theses, and publishing over 200 papers. Hewas an examiner and censor at the RCP, sat on the Management and Grants Committees of the King’s Fund, and for 21 years was physician to HM The Queen. He was treasurer of the RCP from 2003 until being elected president in 2010. He is a trustee of several charities, was a member of an independent monitoring board of a young offenders institute and is a member of the Ministry of Defence Research Ethics Committee. |
|
|
Richard Torbett is Chief Economist at EFPIA. He is responsible for economic analysis as well as EFPIA’s relations with international economic institutions, notably the so-called Troika – the International Monetary Fund, the European Commission’s DG Economic and Financial Affairs (ECFIN) and the European Central Bank. Richard’s current work focuses on the relationship between Health and Economic Growth. |
|
|
Mark Trusheim is the Bio-manufacturing Executive in Residence at the University of Massachusetts Dartmouth and a member of the Massachusetts Bio-Manufacturing Roundtable. In 2004 as Interim President and Board Member of the Massachusetts Biotechnology Council, Mark began working with the University of Massachusetts to develop public, private collaborations as part of an integrated strategy to advance biomanufacturing in the region. Since that time, Massachusetts has seen over $1.5B in public private investment in higher education capabilities and commercial biomanufacturing resulting in New England becoming the world’s largest biopharmaceutical manufacturing region and in 25% biomanufacturing employment growth over the past decade.The University of Massachusetts has helped catalyse the region by expanding the UMass Lowell Biomanufacturing Center, relocating the Massachusetts Biological Laboratories cGMP biologics production to a new facility, creating a Stem Cell Bank at the Medical School to produce and distribute stem cell lines, and constructing two facilities at UMass Dartmouth, a $25M scale-up biomanufacturing facility and a BSL-3 cGMP capable, production suite in its Botulinum Research Center.As an entrepreneur, Mark founded and was the first President and CEO of the diagnostics company Cantata Laboratories. Prior to Cantata, Mark worked at Monsanto/Pharmacia, culminating his career there as Co-President and Chief Operating Officer of Cereon Genomics, LLC–a $500M collaboration with Millennium Pharmaceuticals. Mark is also President of Co-Bio Consulting and is a former Special Government Employee for the FDA’s Office of the Commissioner. Mark holds degrees in Chemistry from Stanford University and Management from the MIT Sloan School of Management, where he also currently holds an appointment as a Visiting Scientist |
|
|
In 1985, Bart joined Janssen Pharmaceutica as a clinical trial monitor. In the course of his career with Janssen, Bart has held a variety of marketing and sales positions, both at local operating company level (e.g. the Netherlands) and at international level. While in the Netherlands he was one of the pioneers that started “Healthy Solutions” a J&J daughter company that focused on developing integrated services in the healthcare field. Later, he was in the core team that developed the initial CRM approach for Janssen EMEA.Between 1999 and 2003, Bart spent 4 years in the IM department of Janssen Pharmaceutica in the US, where he was responsible for the e-business initiatives and for the overall IM technical architecture. Bart joined the EMEA CRM Center of Excellence in April 2003, where he prepared the CRM Roadmap for the short to mid-term.In 2009 Bart was instrumental in developing a new customer-orientation project for Janssen Europe. In 2011 Bart joined the Janssen R&D group to focus on external eHealth / Health Information projects with external partners. Currently, Bart is coordinator of the EMIF (European Medical Information Framework) project, an IMI (Innovative Medicine Initiative) funded project. |
|
|
Andrew Ward is the FT’s pharmaceuticals correspondent from January 2014. In this role, he will cover the business, politics, science and development aspects of the global pharmaceuticals industry. Prior to this, Ward had been UK news editor since November 2011. Previously, Ward served the FT in a number of foreign reporting roles. He was the Nordic bureau chief for two years where he was responsible for coverage of eight countries – Sweden, Norway, Finland, Iceland, Denmark and the three Baltic states of Latvia, Estonia and Lithuania. Ward has also been the White House correspondent, during which he covered the Bush administration and the 2008 presidential election campaign. Before moving to Washington, he spent three years covering business and politics in the Southeast US as Atlanta Correspondent. Between 2001 and 2004, he served as Seoul Correspondent, reporting on North and South Korea. Ward joined the FT in 1999 as a graduate trainee in London and was appointed Media Correspondent in 2000. He received his B.A. in Politics and Modern History from the University of Manchester, UK. |
|
|
Dr. Tim Williams is a Head of Research within the formed Clinical Practice Research Datalink (CPRD) within the Medicines and Healthcare products Regulatory Agency (MHRA). He has an MSc in Epidemiology from London School of Hygiene and Tropical Medicine and PhD in biomedical computing from the University of Leeds. He has worked in the healthcare data field for over 17 years both in academia and within government. As the programme manager for the research group he has oversight of a wide range of projects but his main area of research involves work into observational healthcare data quality and the application of large observational databases to novel areas including Clinical Trial feasibility and delivery. |
|
|
Geoff currently works for GE Healthcare as Global HTA Leader and is interested in all aspects of Health Technology Assessment (HTA) for medical imaging equipment, medical devices and healthcare IT and demonstrating value to support optimal payment for procedures wherever these are carried out – in hospitals & clinics, outpatient, in the community, etc. Previously he worked at Allergan as Head of Pricing, Reimbursement & Health Economics for therapeutic applications of BOTOX® across Europe, Middle East & Africa (EMEA). Before that he was with GlaxoSmithKline (GSK) for 18 years in various positions of responsibility within Europe and globally for pricing & reimbursement of pharmaceutical products. Geoff started his career at Abbott Diagnostics as European Product Manager for in vitro diagnostics. Geoff holds Batchelor’s degree and Doctorate in science – mainly microbiology and cell biology and a Master’s degree in Health Economics from City of London University, UK |
|
|
Stephen Whitehead is Chief Executive of the ABPI and is the chief advocate for the research-based industry in the UK. His career has centred on communications and policy and he is a regular speaker at industry and NHS conferences. Stephen has a strong personal passion and commitment to the pharmaceutical industry and has a vision for the future of healthcare based on patient-centred services and partnership with innovative industry.Earlier in his career Stephen spent 10 years at GlaxoWellcome and Eli Lilly at UK, European and international level. In his last role, Stephen was Group Communications Director at Prudential PLC and prior to that he held leadership roles at Barclays PLC and Allied Domecq PLC. |
